Lanji Pills segmentation by type distinguishes five formulation families that together account for the total market volume. The tablet family, representing roughly 40 % of unit sales, is subdivided into immediate‑release tablets (≈ 25 %) and sustained‑release tablets (≈ 15 %). Immediate‑release tablets dominate retail pharmacy shelves due to low manufacturing cost and rapid onset, while sustained‑release variants target chronic‑care patients requiring prolonged exposure to active phytoconstituents. Capsules constitute about 30 % of the market and include hard‑gelatin capsules (≈ 20 %) and soft‑gel capsules (≈ 10 %). Hard‑gelatin formats are preferred for powder‑filled dosage forms, whereas soft‑gel designs improve bioavailability of lipophilic extracts. The powder segment, accounting for 15 %, is delivered as bulk sachets or granulated mixes; its niche lies in customized dosing and integration into functional beverages. Liquid preparations, such as syrups and tinctures, hold 10 % of sales, driven by pediatric and geriatric acceptance of swallow‑friendly dosage forms. Finally, chewable or lozenge formats, though under 5 %, address consumer demand for on‑the‑go consumption and flavor masking. Collectively, these type sub‑categories define the market taxonomy, with each contributing cost structures, distribution pathways, and regulatory considerations that shape market dynamics.
